Diagnostic and therapeutics company Enzo Biochem Inc (NYSE:ENZ) disclosed on Monday that it recorded a GAAP net loss was USD10.3m ( USD0.22 GAAP net loss per share) for the fiscal year ended 31 July 2018.
This is a dip in earnings when compared with lower GAAP net loss of USD2.5m (USD0.05 GAAP net loss per share) a year ago.
Total revenues of USD104.7m were generated for the fiscal year ended 31 July 2018, a decline of 3.1% from USD107.8m in the prior year. The decline year over year resulted from lower product royalties from an agreement that expired in April 2018.
Consolidated gross margins of 42% were for the fiscal year ended 31 July 2018, a fall over 45% in the prior year.
EBITDA was a loss of USD9.1m for the fiscal year ended 31 July 2018, down against earnings of USD0.7m a year ago.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government